Meeting
2015 ASCO Annual Meeting
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
Authors
Julia M. Greene
San Antonio Military Medical Center, San Antonio, TX
Julia M. Greene , Erika J Schneble , Jonathan Martin , Madeline Flores , John S. Berry IV, Alfred F. Trappey III, Timothy J. Vreeland , Diane F. Hale , Alan K. Sears , Guy T. Clifton , Eric von Hofe , James Thomas Symanowski , Alexandros Ardavanis , Nathan M. Shumway , Sathibalan Ponniah , Michael Papamichail , Sonia A. Perez , George Earl Peoples , Elizabeth Ann Mittendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00524277
Citation
J Clin Oncol 33, 2015 (suppl; abstr 622)
DOI
10.1200/jco.2015.33.15_suppl.622
Abstract #
622
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf
Poster
2011 ASCO Annual Meeting
Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.
First Author: A. K. Sears
Poster
2023 ASCO Annual Meeting
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.
First Author: Hyo S. Han
Poster
2021 ASCO Annual Meeting
The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma.
First Author: Alexandra Adams